<DOC>
	<DOCNO>NCT02104557</DOCNO>
	<brief_summary>Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception And Management Of Endometriosis-Associated Pain</brief_summary>
	<brief_title>Post Marketing Surveillance Study For Sayana®</brief_title>
	<detailed_description>Post Marketing Surveillance require Korea MFDS regulation . Select among patient randomly visit site meet inclusion/exclusion criterion .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Subjects legally authorize representative pediatric subject agree provide write informed consent form ( ie , data privacy statement ) . 2.Women subject initiate treatment Sayana® first time per local product document usage Known suspect pregnancy . Undiagnosed vaginal bleeding . Known suspected malignancy breast . Active thrombophlebitis , current past history thromboembolic disorder , cerebral vascular disease . Significant liver disease . Known hypersensitivity medroxyprogesterone acetate ingredient . Women menarche postmenopausal . Treatment investigational agent device within 30 day prior enrollment visit .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sayana</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Contraception</keyword>
	<keyword>Endometriosis-associated pain</keyword>
	<keyword>PMS</keyword>
	<keyword>Post Marketing Surveillance</keyword>
</DOC>